Skip to main content
Equibles
OVID logo

OVID · Ovid Therapeutics Inc.

Track OVID — free

Use OVID with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about OVID

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.84 +0.01 (+0.18%)
Market Cap
$552.69M
Shares
195.30M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-08-13 Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
2026-07-08 Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
2026-06-04 Ovid Therapeutics to Participate in Upcoming Investor Conferences
2026-06-03 Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
2026-05-12 Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
2026-04-08 Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
2026-03-18 Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-18 Ovid Therapeutics Announces Pricing of $60 Million Private Placement
2026-02-25 Ovid Therapeutics to Participate in Upcoming Investor Conferences
2025-12-18 Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
2025-12-02 Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
2025-11-12 Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Past events

Date Event Type
2026-06-15 H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference Conference
2026-04-14 KCC2 Deep Dive R&D Event Event
2026-03-18 Earnings conference call (announced in 8-K) Earnings call
2026-03-09 Leerink Global Healthcare Conference Conference
2026-03-04 TD Cowen 46th Annual Health Care Conference Conference
2026-02-25 Oppenheimer 36th Annual Healthcare Life Sciences Conference Conference
2025-10-03 OV329 topline results webcast from the phase 1 healthy volunteer study Earnings call
2025-06-12 Biomarkers in Epilepsy Investor Event Event
2025-04-07 24th Annual Needham Virtual Healthcare Conference Conference
2025-03-03 TD Cowen 45th Annual Health Care Conference Conference
2025-02-12 Oppenheimer 35th Annual Healthcare Life Sciences Conference Conference
2024-11-13 KCC2 Download Day Event
2024-09-19 2024 Cantor Global Healthcare Conference Conference
2024-09-10 H.C. Wainwright 26th Annual Global Investment Conference Conference
2024-05-20 H.C. Wainwright 2nd Annual BioConnect Investor Conference Conference
2024-04-11 23rd Annual Needham Virtual Healthcare Conference Conference
2024-03-06 TD Cowen 44th Annual Health Care Conference Conference
2024-02-13 Oppenheimer 34th Annual Healthcare Life Sciences Conference Conference
2023-10-12 Jefferies Biotech CNS/Neuro Summit Event
2023-10-02 Ovid R&D Day Event
2023-09-26 2023 Cantor Fitzgerald Global Healthcare Conference Conference
2023-09-12 H.C. Wainwright 25th Annual Global Investment Conference Conference
2023-04-17 22nd Annual Needham Virtual Healthcare Conference Conference
2023-03-15 2nd Annual Needham Virtual Neuroscience Forum Event
2023-03-06 Cowen 43rd Annual Health Care Conference Conference

Source: https://investors.ovidrx.com/overview/default.aspx

Key facts CIK 1636651 CUSIP 690469101 13F (30d) 134 filings 128 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)